Diabetes and COVID-19: IDF perspective in the Western Pacific region

doi:10.1016/j.diabres.2020.108278

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24907

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24907

Title:	Diabetes and COVID-19: IDF perspective in the Western Pacific region
Authors:	Hwang, Y;Khasag, A;Jia, WP;Jenkins, A;Huang, CN;Yabe, D;Kim, DM;Kadowaki, T;Lee, MK
Keywords:	Diabetes;COVID-19
Date:	2020
Issue Date:	2022-08-09T08:09:56Z (UTC)
Publisher:	ELSEVIER IRELAND LTD
ISSN:	0168-8227
Abstract:	The World Health Organization (WHO) declared a pandemic, the highest risk level in the infectious disease alert phase, on 11 March 2020. In the Western Pacific Region (WPR), 192,016 confirmed cases with 7125 deaths had been reported as of 8 June 2020. In people with diabetes COVID-19 can be more difficult to treat due to the wide fluctuations in blood glucose levels or presence of comorbidities such as diabetes complications, including cardiovascular disease and renal damage, which are recognized risks for adverse outcomes. National diabetes associations and governments have established guidelines for subjects with diabetes in relation to COVID-19, and are trying to supply emergency and their regularly required medical products for them. The WPR is so large and composed of such diverse countries and COVID-19 situations, no one conclusion or program applies. Instead we could see a diverse COVID-19 pandemic pro file in the WPR, and several creative diagnostic and therapeutic measures undertaken. This includes drive-through screening facilities, high-speed RT-PCR technologies, convalescent patients' plasma therapy, which potentially had some positive contributions in combatting COVID-19 in the WPR as well as globally. Although the numbers of confirmed cases are currently decreasing in the region, the COVID-19 pandemic is not over, and many experts are recommending to prepare measures for potential second or third waves of COVID-19. (C) 2020 Elsevier B.V. All rights reserved.
URI:	http://dx.doi.org/10.1016/j.diabres.2020.108278 https://www.webofscience.com/wos/woscc/full-record/WOS:000572845000003 https://ir.csmu.edu.tw:8080/handle/310902500/24907
Relation:	DIABETES RESEARCH AND CLINICAL PRACTICE ,2020 ,v166
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	177	View/Open

Loading...